CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Kulkarni Samarth | Chief Executive Officer | Mar 11 '25 | Sale | 42.42 | 9,973 | 423,055 | 180,890 | Mar 12 07:05 PM | | Kulkarni Samarth | Chief Executive Officer | Mar 12 '25 | Sale | 43.32 | 4,462 | 193,294 | 185,428 | Mar 12 07:05 PM | | KASINGER JAMES R. | General Counsel and Secretary | Mar 11 '25 | Sale | 42.42 | 2,850 | 120,897 | 77,530 | Mar 12 07:05 PM | | KASINGER JAMES R. | General Counsel and Secretary | Mar 12 '25 | Sale | 43.32 | 1,116 | 48,345 | 78,664 | Mar 12 07:05 PM | | Bruno Julianne | Chief Operating Officer | Mar 11 '25 | Sale | 42.42 | 1,198 | 50,819 | 8,263 | Mar 12 07:05 PM | | Bruno Julianne | Chief Operating Officer | Mar 12 '25 | Sale | 43.32 | 190 | 8,231 | 8,508 | Mar 12 07:05 PM | | Greene John | Director | Feb 26 '25 | Buy | 44.85 | 7,000 | 313,948 | 7,000 | Feb 28 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Feb 19 '25 | Sale | 55.20 | 18,360 | 1,013,564 | 171,613 | Feb 21 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Feb 18 '25 | Sale | 55.05 | 11,640 | 640,782 | 196,901 | Feb 19 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Feb 19 '25 | Sale | 52.80 | 6,928 | 365,798 | 189,973 | Feb 19 05:35 PM | | Bruno Julianne | Chief Operating Officer | Feb 19 '25 | Sale | 52.80 | 333 | 17,582 | 7,062 | Feb 19 05:35 PM | | KASINGER JAMES R. | General Counsel and Secretary | Feb 18 '25 | Sale | 53.85 | 9,595 | 516,691 | 73,002 | Feb 19 05:35 PM | | KASINGER JAMES R. | General Counsel and Secretary | Feb 19 '25 | Sale | 52.80 | 1,947 | 102,802 | 74,880 | Feb 19 05:35 PM | | Samarth Kulkarni | Officer | Feb 18 '25 | Proposed Sale | 52.22 | 45,000 | 2,349,900 | | Feb 18 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Dec 24 '24 | Option Exercise | 16.21 | 13,751 | 222,904 | 195,291 | Dec 27 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Dec 02 '24 | Sale | 55.10 | 15,000 | 826,564 | 181,540 | Dec 04 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Nov 11 '24 | Sale | 55.62 | 30,000 | 1,668,678 | 196,540 | Nov 13 05:35 PM | | KASINGER JAMES R. | General Counsel and Secretary | Oct 14 '24 | Sale | 46.28 | 1,089 | 50,399 | 62,597 | Oct 15 06:00 PM | | Kulkarni Samarth | Chief Executive Officer | Oct 14 '24 | Sale | 46.28 | 4,293 | 198,680 | 226,540 | Oct 15 06:00 PM | | Bruno Julianne | Chief Operating Officer | Jun 21 '24 | Sale | 56.09 | 3,366 | 188,799 | 6,745 | Jun 24 05:35 PM | | Kulkarni Samarth | Chief Executive Officer | Apr 15 '24 | Option Exercise | 19.12 | 19,582 | 374,408 | 227,704 | Apr 17 05:45 PM | | Kulkarni Samarth | Chief Executive Officer | Apr 15 '24 | Sale | 59.91 | 19,582 | 1,173,232 | 208,122 | Apr 17 05:45 PM | | Prasad Raju | Chief Financial Officer | Mar 15 '24 | Sale | 72.69 | 3,524 | 256,160 | 6,476 | Mar 18 05:45 PM | | Kulkarni Samarth | Chief Executive Officer | Mar 15 '24 | Option Exercise | 19.12 | 20,000 | 382,400 | 228,122 | Mar 18 05:45 PM | | Kulkarni Samarth | Chief Executive Officer | Mar 15 '24 | Sale | 72.48 | 20,000 | 1,449,628 | 208,122 | Mar 18 05:45 PM |
|
